Lakeside Holding (LSH) H1 2026 earnings summary

Executive summary

• Revenue for the quarter ended December 31, 2025, was $7.0 million, up 95% year-over-year, with gross profit of $1.9 million compared to a gross loss in the prior year.

• For the six months ended December 31, 2025, revenue reached $13.1 million, a 71% increase year-over-year, and gross profit was $3.0 million, up from $0.5 million.

• The company expanded into pharmaceutical distribution, contributing $2.4 million in quarterly revenue and $3.8 million for the six months.

• Net loss for the quarter was $1.6 million, an improvement from $1.9 million in the prior year; six-month net loss was $2.9 million, improved from $3.3 million.

Financial highlights

• Cross-border airfreight revenue rose 81% to $3.6 million for the quarter; ocean freight revenue declined 31% to $0.9 million.

• Gross margin for cross-border freight improved to 14.5% from -4.1% year-over-year; pharmaceutical distribution margin was 51.1%.

• Selling expenses increased to $0.9 million for the quarter, mainly due to the new pharmaceutical segment.

• General and administrative expenses rose 15.6% to $2.2 million for the quarter, driven by consulting and expansion costs.

• Interest expense for the quarter was $183,449, up 349% due to higher loan balances and convertible debt.

Outlook and guidance

• Management plans to continue expanding the customer base and service offerings, especially in the healthcare sector.

• The company is focused on cost control, operational efficiency, and strategic acquisitions to drive future growth.

• Ongoing trade policy uncertainty and regulatory risks in both logistics and pharmaceuticals are being closely monitored.